Personalizing treatment for patients with HR-positive, HER2-negative metastatic breast cancer using fulvestrant, elacestrant, capivasertib, capecitabine, or a drug combination.

Registered drugNo placebo

Personalizing treatment for patients with HR-positive, HER2-negative metastatic breast cancer using fulvestrant, elacestrant, capivasertib, capecitabine, or a drug combination.

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Centro Di Riferimento Oncologico Di Aviano

Contact Research Centre

Osteoporosis postmenopausal

Not yet recruiting

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Registered drugNo placebo

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Denosumab
Sponsor:Ospedale Galeazzi S.p.A.

Contact Research Centre

Breast cancer

Not yet recruiting

A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

Registered drugNo placebo

A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ribociclib
Sponsor:Fondazione Oncotech Impresa Sociale

Contact Research Centre

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trials Carboplatin86 clinical trials Pembrolizumab77 clinical trials Letrozole73 clinical trials Fulvestrant58 clinical trials Docetaxel49 clinical trials Enzalutamide49 clinical trials Exemestane46 clinical trials Anastrozole44 clinical trials

Reproductive system and breast disorders – page 37

Conditions in this area

Clinical trials in Reproductive system and breast disorders

956 clinical trials

Infertility male

Follitropin Alfa and Chorionic Gonadotrophin for Men with Male Infertility, Low Testosterone, and Low Sperm Count

Lymphogranuloma venereum

Doxycycline for Asymptomatic Anal LGV Infection in Patients with Asymptomatic Anal LGV Infection

Hepatocellular carcinoma+5

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

Vulval cancer

A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

Hormone receptor positive HER2 negative breast cancer

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Infertility male

Study evaluating the effect of isotretinoin on sperm production in men with low sperm count

Hormone-refractory prostate cancer

Comparison of standard dosing and blood level monitoring of abiraterone acetate for patients with metastatic castration-resistant prostate cancer

Endometrial adenocarcinoma

A study of tirzepatide and levonorgestrel in women with endometrial cancer

Bacterial vaginosis

Using a drug combination to treat vaginal flora abnormalities in pregnant women at high risk of preterm birth.

Breast cancer metastatic

Personalizing treatment for patients with HR-positive, HER2-negative metastatic breast cancer using fulvestrant, elacestrant, capivasertib, capecitabine, or a drug combination.

Osteoporosis postmenopausal

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Breast cancer

A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.